Soledad Gallego
Overview
Explore the profile of Soledad Gallego including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
1063
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gallo-Oller G, Pons G, Sansa-Girona J, Navarro N, Zarzosa P, Garcia-Gilabert L, et al.
Exp Hematol Oncol
. 2024 Apr;
13(1):38.
PMID: 38581035
Rhabdomyosarcoma (RMS), such as other childhood tumors, has witnessed treatment advancements in recent years. However, high-risk patients continue to face poor survival rates, often attributed to the presence of the...
2.
Ewijk R, Chatziantoniou C, Adams M, Bertolini P, Bisogno G, Bouhamama A, et al.
Pediatr Radiol
. 2023 Sep;
53(12):2539-2551.
PMID: 37682330
Objective: To investigate the feasibility of diffusion-weighted magnetic resonance imaging (DW-MRI) as a predictive imaging marker after neoadjuvant chemotherapy in patients with rhabdomyosarcoma. Material And Methods: We performed a multicenter...
3.
Pons G, Gallo-Oller G, Navarro N, Zarzosa P, Sansa-Girona J, Garcia-Gilabert L, et al.
Cancers (Basel)
. 2023 Mar;
15(6).
PMID: 36980521
The identification of novel therapeutic targets for specific cancer molecular subtypes is crucial for the development of precision oncology. In the last few years, CRISPR/Cas9 screens have accelerated the discovery...
4.
Bisogno G, Minard-Colin V, Zanetti I, Ferrari A, Gallego S, Davila Fajardo R, et al.
J Clin Oncol
. 2023 Feb;
41(13):2342-2349.
PMID: 36848614
JCO The RMS2005 study included two phase III randomized trials for high-risk (HR) and observational trials for low (LR), standard (SR), and very high-risk (VHR) patients who have been partially...
5.
Zarzosa P, Garcia-Gilabert L, Hladun R, Guillen G, Gallo-Oller G, Pons G, et al.
Cancers (Basel)
. 2023 Feb;
15(3).
PMID: 36765685
Aberrant activation of the Hedgehog (Hh) signalling pathway is known to play an oncogenic role in a wide range of cancers; in the particular case of rhabdomyosarcoma, this pathway has...
6.
Mercolini F, Merks J, Minard-Colin V, Cameron A, van Scheltinga S, Sher O, et al.
Pediatr Blood Cancer
. 2022 Dec;
70(3):e30143.
PMID: 36519598
Background: The prognosis of patients with metastatic rhabdomyosarcoma (RMS) is not uniformly poor. Tumors with nodal involvement beyond the first lymph node station are currently considered to have distant metastases....
7.
Navarro N, Molist C, Sansa-Girona J, Zarzosa P, Gallo-Oller G, Pons G, et al.
Cell Mol Life Sci
. 2022 Oct;
79(11):546.
PMID: 36221013
The majority of current cancer therapies are aimed at reducing tumour growth, but there is lack of viable pharmacological options to reduce the formation of metastasis. This is a paradox,...
8.
Jimenez C, Antonelli R, Nadal-Ribelles M, Devis-Jauregui L, Latorre P, Sole C, et al.
Mol Cancer
. 2022 Sep;
21(1):175.
PMID: 36057593
Background: Epigenetic programming during development is essential for determining cell lineages, and alterations in this programming contribute to the initiation of embryonal tumour development. In neuroblastoma, neural crest progenitors block...
9.
Ben-Arush M, Minard-Colin V, Scarzello G, Fajardo R, Terwisscha van Scheltinga S, Bernier V, et al.
Eur J Cancer
. 2022 Jun;
172:119-129.
PMID: 35763871
Purpose: Regional lymph node disease (N1) is a component of the risk-based treatment stratification in rhabdomyosarcoma (RMS). The purpose of this study was to determine the contribution of nodal disease...
10.
Trippett T, Toledano H, Campbell Hewson Q, Verschuur A, Langevin A, Aerts I, et al.
Target Oncol
. 2022 Jun;
17(3):283-293.
PMID: 35715627
Background: The MAPK pathway is an emerging target across a number of adult and pediatric tumors. Targeting the downstream effector of MAPK, MEK1, is a proposed strategy to control the...